Transforming the lives of airways disease patients

Vectura is an industry-leading device & formulation business for inhaled airways disease.

 

Background

  • Recurring revenues driven by on-market partnered products, underpinned by a robust pipeline
  • Consilium appointed to provide strategic IR and communications guidance to enlarged Vectura Group post-merger with Skyepharma in 2016

£441m

merger with Skyepharma

 

Our strategy

  • Strategic advice and sounding board to mangement and IR team
  • Onboarding of new CFO and CEO in 2018 and 2019 respectively
  • Review of corporate materials including website, key messaging, presentation, Q&A to reflect change in strategy towards CDMO business
  • Support with ongoing communication of the CDMO story and strategy to key stakeholders

 

Outcome

  • Smooth transition from development to services business
  • Positive reception by key stakeholders to re-focused CDMO business model